CGT4859

Phase 2Small molecule

CCogent Biosciences, Inc.

CGT4859 is one of 39 small molecule programs targeting Cholangiocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CholangiocarcinomaRecruiting

CholangiocarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

45 competitors in Cholangiocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

19 2

Zykadia

Rocaltrol

Camptosar

Colcrys

Ixempra

Wellcovorin

GGlaxo Dba Glaxosmithkline

Approved

—8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

14 9

Tecentriq

Roche

Phase 3

3 10

Cotellic

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Cholangiocarcinoma

NCT06777316

Clinical

Trials by Indication[1]

Cholangiocarcinoma1 trial

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Recruiting·CCogent Biosciences, Inc.·Phase 1/2·NCT06777316·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CGT4859. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CGT4859 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CGT4859. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cogent Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCogent Biosciences, Inc.

CGT4859

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News